Nick Flynn

Mr. Nick Flynn

Biochemical Genetics Unit, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, UK
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2014 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Closed access
Nick FlynnNick Flynn
Nick Flynn
ADA Dawnay
A Dawnay
Background: Acute kidney injury (AKI) is frequently under-recognized and contributes to poor outcomes. Electronic alerts (e-alerts) to highlight AKI based on changes in serum creatinine may facilitate earlier recognition and treatment, and sophisticated algorithms for AKI detection have been proposed or implemented elsewhere. However, many laboratories currently lack the resources or capability to replicate these systems. Methods: A real-time automated delta check e-alert flags a 50% increase in creatinine to a concentration of >50 µmol/L from the most recent result within a 90-day period and automatically adds the comment ‘?AKI – creatinine increase >50% from previous’ with a link to local AKI guidelines. In addition, creatinine results >300 µmol/L are retrospectively reviewed and phoned if AKI is suspected. For each alert over a 12-day period we manually reviewed previous and subsequent creatinine results to determine baseline creatinine and stage AKI according to Acute Kidney Injury Network (AKIN) criteria. Results: From 11,930 creatinine requests, 63 of 90 (70%) delta check e-alerts were due to AKI, identifying 61 episodes of AKI. Thirty four of 54 (63%) creatinine results >300 µmol/L were due to AKI, identifying a further 10 episodes of AKI. The positive predictive value (PPV) for AKI of a delta check e-alert was greater when the trigger creatinine was >100 µmol/L (PPV 89%) or when the absolute change in creatinine was >50 µmol/L (PPV 93%). Conclusion: This study demonstrates that a simple automated delta check can detect and flag AKI in real time, continuously, at little extra cost and without manual input.

2 September 2013 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
Nick FlynnNick Flynn
Nick Flynn
FLF Lam
F Lam
ADA Dawnay
A Dawnay
Background: 3-epi-25-hydroxyvitamin D 3 (3-epi-25OHD 3 ) interferes in most liquid chromatography-tandem mass spectrometry (LC-MS/MS) assays for 25-hydroxyvitamin D (25OHD). The clinical significance of this is unclear, with concentrations from undetectable to 230 nmol/L reported. Many studies have quantified 3-epi-25OHD 3 based on 25OHD 3 calibrators or other indirect methods, and we speculated that this contributes to the observed variability in reported 3-epi-25OHD 3 concentrations. Methods: We compared continuous MS/MS infusions of 3-epi-25OHD 3 and 25OHD 3 solutions, spiked both analytes into the same serum matrix and analysed patient samples to assess the effect of three different quantitation methods on 3-epi-25OHD 3 concentration. Experiments were performed on an LC-MS/MS system using a phenyl column which does not resolve 3-epi-25OHD 3 , and a modified method utilizing a Zorbax SB-CN column that chromatographically resolves 3-epi-25OHD 3 from 25OHD 3 . Results: A greater 3-epi-25OHD 3 signal, compared with 25OHD 3 , was observed during equimolar post-column continuous infusion of analyte solutions, and following analysis of a serum pool spiked with both analytes. 3-epi-25OHD 3 signal enhancement was dependent on mobile phase composition. Compared with 3-epi-25OHD 3 calibrators, indirect quantitation methods resulted in up to 10 times as many samples having 3-epi-25OHD 3 concentrations ≥ 10 nmol/L, and an approximately fourfold increase in the maximum observed 3-epi-25OHD 3 concentration to 95 nmol/L. Conclusions: Enhanced 3-epi-25OHD 3 signal leads to overestimation of its concentrations in the indirect quantitation methods used in many previous studies. The enhanced signal may contribute to greater interference in some 25OHD LC-MS/MS assays than others. We highlight that equimolar responses cannot be assumed in LC-MS/MS systems, even if two molecules are structurally similar.

3 June 2023 in Clinica Chimica Acta
Verified
Journal Article
Closed access
Nick FlynnNick Flynn
Nick Flynn
SMStuart J. Moat
Stuart J. Moat
SHSarah L. Hogg
Sarah L. Hogg

Verified
Journal Article
Open access
PDF file
SMStuart Moat
Stuart Moat
James BonhamJames Bonham
James Bonham
CCChristine Cavanagh
Christine Cavanagh
MBMargaret Birch
Margaret Birch
GGGriffith Griffith
Griffith Griffith
LTLESLEY JACQUELINE TETLOW
LESLEY JACQUELINE TETLOW
In 2015, U.K. newborn screening (NBS) laboratory guidelines were introduced to standardize dried blood spot (DBS) specimen quality acceptance and specify a minimum acceptable DBS diameter of ≥7 mm. The UK ‘acceptable’ avoidable repeat rate (AVRR) is ≤2%. To assess inter-laboratory variability in specimen acceptance/rejection, two sets of colored scanned images (n = 40/set) of both good and poor-quality DBS specimens were distributed to all 16 U.K. NBS laboratories for evaluation as part of an external quality assurance (EQA) assessment. The mean (range) number of specimens rejected in the first EQA distribution was 7 (1–16) and in the second EQA distribution was 7 (0–16), demonstrating that adherence to the 2015 guidelines was highly variable. A new minimum standard for DBS size of ≥8 mm (to enable a minimum of six sub-punches from two DBS) was discussed. NBS laboratories undertook a prospective audit and demonstrated that using ≥8 mm as the minimum acceptable DBS diameter would increase the AVRR from 2.1% (range 0.55% to 5.5%) to 7.8% (range 0.55% to 22.7%). A significant inverse association between the number of specimens rejected in the DBS EQA distributions and the predicted AVVR (using ≥8 mm minimum standard) was observed (r = −0.734, p = 0.003). Before implementing more stringent standards, the impact of a standard operating procedure (SOP) designed to enable a standardized approach of visual assessment and using the existing ≥7 mm diameter (to enable a minimum of four sub-punches from two DBS) as the minimum standard was assessed in a retrospective audit. Implementation of the SOP and using the ≥7 mm DBS diameter would increase the AVRR from 2.3% (range 0.63% to 5.3%) to 6.5% (range 4.3% to 20.9%). The results demonstrate that there is inconsistency in applying the acceptance/rejection criteria, and that a low AVVR is not an indication of good-quality specimens being received into laboratories. Further work is underway to introduce and maintain standards without increasing the AVRR to unacceptable levels.

Verified
Journal Article
Open access
PDF file
RCRachel Carling
Rachel Carling
KHKaty Hedgethorne
Katy Hedgethorne
ACAnupam Chakrapani
Anupam Chakrapani
PHPatricia Hall
Patricia Hall
Nick FlynnNick Flynn
Nick Flynn
James BonhamJames Bonham
James Bonham
Since the UK commenced newborn screening for isovaleric acidemia in 2015, changes in prescribing have increased the incidence of false positive (FP) results due to pivaloylcarnitine. A review of screening results between 2015 and 2022 identified 24 true positive (TP) and 84 FP cases, with pivalate interference confirmed in 76/84. Initial C5 carnitine (C5C) did not discriminate between FP and TP with median (range) C5C of 2.9 (2.0–9.6) and 4.0 (1.8–>70) µmol/L, respectively, and neither did Precision Newborn Screening via Collaborative Laboratory Integrated Reports (CLIR), which identified only 1/47 FP cases. However, among the TP cases, disease severity showed a correlation with initial C5C in ‘asymptomatic’ individuals (n = 17), demonstrating a median (range) C5C of 3.0 (1.8–7.1) whilst ‘clinically affected’ patients (n = 7), showed a median (range) C5C of 13.9 (7.7–70) µmol/L. These findings allowed the introduction of dual cut-off values into the screening algorithm to reduce the incidence of FPs, with initial C5C results ≥ 5 µmol/L triggering urgent referral, and those >2.0 and <5.0 µmol/L prompting second-tier C5-isobar testing. This will avoid delayed referral in babies at particular risk whilst reducing the FP rate for the remainder.

11 October 2025 in Clinica Chimica Acta
Verified
Journal Article
Closed access
Nick FlynnNick Flynn
Nick Flynn
SMStuart J. Moat
Stuart J. Moat
SHSarah L. Hogg
Sarah L. Hogg